Arrivent biopharma inc AVBP.US 總覽分析
AVBP 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
AVBP 近期報酬表現
1.04%
Arrivent biopharma inc
3.56%
同產業平均
1.47%
S&P500
與 AVBP 同產業的標的表現
- BBIO Bridgebio pharma inc價值 2 分趨勢 4 分波段 5 分籌碼 4 分股利 1 分查看更多
AVBP 公司資訊
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.